Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacturing of peptides and oligonucleotides for research, clinical development, and commercial applications. Founded in 1971 by Peter Grogg as Bachem Feinchemikalien AG in Liestal near Basel, it has grown into a global leader with over 50 years of expertise in peptide synthesis and complex organic compounds as active pharmaceutical ingredients. Headquartered in Bubendorf, Switzerland, the company operates production sites in Vionnaz (Switzerland), Vista and Torrance (California, USA), and St Helens (UK), alongside sales offices in Europe, Asia, and the US. Bachem Holding AG serves pharmaceutical and biotechnology firms worldwide, offering comprehensive services including GMP-compliant production and process development for peptide-based biochemicals. Key milestones include its public listing on the SIX Swiss Exchange in 1998, acquisitions like American Peptide in 2015, and expansion into oligonucleotides since 2018. With a commitment to innovation, sustainability, and operational excellence, it plays a vital role in advancing biopharmaceutical supply chains.